XOFIGO

This brand name is authorized in Austria, Brazil, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland, Singapore, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug XOFIGO contains one active pharmaceutical ingredient (API):

1 Radium-223 dichloride
UNII RJ00KV3VTG - RADIUM RA-223 DICHLORIDE

Radium-223 dichloride mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. Radium-223 dichloride monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).

Read about Radium-223 dichloride

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
XOFIGO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
V10XX03 V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals
Discover more medicines within V10XX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 538916110027307
Country: EE Ravimiamet Identifier(s): 1632293
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 113873001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 559995
Country: FR Base de données publique des médicaments Identifier(s): 66302387
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 375222
Country: HK Department of Health Drug Office Identifier(s): 64332
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7423
Country: IT Agenzia del Farmaco Identifier(s): 043116019
Country: JP 医薬品医療機器総合機構 Identifier(s): 4291432A1025
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1072067
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100313552
Country: SG Health Sciences Authority Identifier(s): 14478P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699546770083
Country: US FDA, National Drug Code Identifier(s): 50419-208
Country: ZA Health Products Regulatory Authority Identifier(s): 48/32.15/0715

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.